Emerging Technologies for the Assessment and Treatment of Hemostasis (Bleeding and/or Thrombosis) Disorders
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 3708
Special Issue Editor
Interests: hemostasis/haemostasis; thrombosis; von willebrand factor/VWF; von willebrand disease/VWD; coagulation; platelet function; thrombophilia; lupus anticoagulant; antiphospholipid antibodies
Special Issue Information
Dear Colleagues,
The field of hemostasis and thrombosis is continually advancing. In this Special Issue, we will explore emerging technologies in the field related to both the assessment and treatment of associated disorders. Hemostasis is a homeostatic mechanism that helps to maintain blood flow in the circulation and to prevent bleeding; thus, imbalance or dysfunction in this process can lead to adverse bleeding or thrombosis. In either case, patients with suspected thrombosis or bleeding can be investigated via a multitude of approaches and methods, and treatment or therapy can also be achieved using a variety of approaches and management tools. In this issue, we wish to explore the current state of the art. For example, historical approaches to managing hemophilia were largely restricted to replacement therapy using plasma-derived factor concentrates. Nowadays, there is a plethora of options in addition to plasma-derived factor concentrates, including replacement with recombinant factors, extended life factor products and nonfactor replacement therapies that mimic the activity of the missing factors. In terms of the assessment of hemophilia and hemophilia therapy, the past practice involved one-stage factor clotting assays. In contemporary times, this has been expanded to the use of various chromogenic assays, which can be specifically tailored, to measuring either the replacement factor products or the alternate therapies, to other procedures such as thrombin generation. In terms of thrombosis management, the armamentarium was once restricted to heparin, warfarin and aspirin. The available tools for this purpose have since been extended, first with the emergence of direct oral anticoagulants (DOACs), and currently with many novel products under investigation. Against this background, high-quality submissions related to the contemporary and emerging assessment (clinical and/or laboratory) and treatment/management of bleeding or thrombosis disorders will be considered for this Special Issue.
Dr. Emmanuel Favaloro
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
